UTHR

SEC source: 0001106578-26-000015 · primarydocument.xml · nonDerivative · entry 6

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,493

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F6 · price: This transaction was executed in multiple trades at prices ranging from $527.42 to $528.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000015 · primarydocument.xml · nonDerivative · entry 5

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,225

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F5 · price: This transaction was executed in multiple trades at prices ranging from $526.42 to $527.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000015 · primarydocument.xml · nonDerivative · entry 4

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,096

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F4 · price: This transaction was executed in multiple trades at prices ranging from $525.40 to $526.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000015 · primarydocument.xml · nonDerivative · entry 3

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,642

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F3 · price: This transaction was executed in multiple trades at prices ranging from $524.36 to $525.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000015 · primarydocument.xml · nonDerivative · entry 2

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,973

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F2 · price: This transaction was executed in multiple trades at prices ranging from $522.77 to $523.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000015 · primarydocument.xml · nonDerivative · entry 1

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,013

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

SEC source: 0002028640-26-000006 · primarydocument.xml · nonDerivative · entry 1

MALCOLM JAN · CIK 0002028640 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125

F1 · kind: This sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 11, 2025.

SEC source: 0001106578-26-000014 · primarydocument.xml · derivative · entry 18

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,000

Underlying: Common Stock · 9,500 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

SEC source: 0001106578-26-000014 · primarydocument.xml · nonDerivative · entry 12

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,513

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

SEC source: 0001106578-26-000014 · primarydocument.xml · nonDerivative · entry 11

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,593

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F11 · price: This transaction was executed in multiple trades at prices ranging from $539.83 to $540.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000014 · primarydocument.xml · nonDerivative · entry 10

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,373

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F10 · price: This transaction was executed in multiple trades at prices ranging from $538.81 to $539.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000014 · primarydocument.xml · nonDerivative · entry 9

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,082

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F9 · price: This transaction was executed in multiple trades at prices ranging from $537.81 to $538.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000014 · primarydocument.xml · nonDerivative · entry 8

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,173

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F8 · price: This transaction was executed in multiple trades at prices ranging from $536.79 to $537.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000014 · primarydocument.xml · nonDerivative · entry 7

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,173

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F7 · price: This transaction was executed in multiple trades at prices ranging from $535.74 to $536.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000014 · primarydocument.xml · nonDerivative · entry 6

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,013

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F6 · price: This transaction was executed in multiple trades at prices ranging from $534.63 to $535.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000014 · primarydocument.xml · nonDerivative · entry 5

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,740

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F5 · price: This transaction was executed in multiple trades at prices ranging from $533.62 to $534.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000014 · primarydocument.xml · nonDerivative · entry 4

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,816

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F4 · price: This transaction was executed in multiple trades at prices ranging from $532.62 to $533.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000014 · primarydocument.xml · nonDerivative · entry 3

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,483

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F3 · price: This transaction was executed in multiple trades at prices ranging from $531.62 to $532.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000014 · primarydocument.xml · nonDerivative · entry 2

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,880

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F2 · price: This transaction was executed in multiple trades at prices ranging from $530.53 to $531.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000014 · primarydocument.xml · nonDerivative · entry 1

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,013

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

SEC source: 0001605729-26-000005 · primarydocument.xml · nonDerivative · entry 1

Olian Judy D. · CIK 0001605729 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,445

F1 · kind: This is a sale of common stock pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 24, 2025.

SEC source: 0001106578-26-000010 · primarydocument.xml · nonDerivative · entry 4

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,414

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F4 · price: This transaction was executed in multiple trades at prices ranging from $534.42 to $535.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected

SEC source: 0001106578-26-000013 · primarydocument.xml · derivative · entry 16

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,500

Underlying: Common Stock · 9,500 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

SEC source: 0001106578-26-000013 · primarydocument.xml · nonDerivative · entry 10

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,513

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

SEC source: 0001106578-26-000013 · primarydocument.xml · nonDerivative · entry 9

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,673

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F9 · price: This transaction was executed in multiple trades at prices ranging from $536.16 to $536.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000013 · primarydocument.xml · nonDerivative · entry 8

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,436

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F8 · price: This transaction was executed in multiple trades at prices ranging from $535.14 to $536.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000013 · primarydocument.xml · nonDerivative · entry 7

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,987

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F7 · price: This transaction was executed in multiple trades at prices ranging from $534.12 to $535.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000013 · primarydocument.xml · nonDerivative · entry 6

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,766

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F6 · price: This transaction was executed in multiple trades at prices ranging from $533.12 to $534.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000013 · primarydocument.xml · nonDerivative · entry 5

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,292

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F5 · price: This transaction was executed in multiple trades at prices ranging from $532.10 to $533.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000013 · primarydocument.xml · nonDerivative · entry 4

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,889

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F4 · price: This transaction was executed in multiple trades at prices ranging from $531.10 to $532.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000013 · primarydocument.xml · nonDerivative · entry 3

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,453

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F3 · price: This transaction was executed in multiple trades at prices ranging from $530.03 to $531.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000013 · primarydocument.xml · nonDerivative · entry 2

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,653

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

F2 · price: This transaction was executed in multiple trades at prices ranging from $528.51 to $529.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001106578-26-000013 · primarydocument.xml · nonDerivative · entry 1

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,013

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

SEC source: 0001636178-26-000002 · primarydocument.xml · derivative · entry 6

EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,098 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · derivative.exercise_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023.

F4 · derivative.expiration_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023.

SEC source: 0001636178-26-000002 · primarydocument.xml · derivative · entry 5

EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,380 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · derivative.exercise_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023.

F4 · derivative.expiration_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023.

SEC source: 0001636178-26-000002 · primarydocument.xml · nonDerivative · entry 4

EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,876

F3 · shares: Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units.

SEC source: 0001636178-26-000002 · primarydocument.xml · nonDerivative · entry 3

EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,980

F3 · shares: Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units.

SEC source: 0001636178-26-000002 · primarydocument.xml · nonDerivative · entry 2

EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,662

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

SEC source: 0001636178-26-000002 · primarydocument.xml · nonDerivative · entry 1

EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,564

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F2 · balance_after: Includes 42 shares of common stock acquired on March 4, 2026 under the United Therapeutics Employee Stock Purchase Plan.

SEC source: 0001673232-26-000013 · primarydocument.xml · derivative · entry 7

BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 0

Underlying: Common Stock · 15,592 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F5 · derivative.exercise_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023.

F5 · derivative.expiration_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023.

F2 · ownership.nature: Securities held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power.

SEC source: 0001673232-26-000013 · primarydocument.xml · derivative · entry 6

BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 0

Underlying: Common Stock · 17,790 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F5 · derivative.exercise_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023.

F5 · derivative.expiration_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023.

F2 · ownership.nature: Securities held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power.

SEC source: 0001673232-26-000013 · primarydocument.xml · nonDerivative · entry 4

BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 19,046

F3 · shares: Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units.

F2 · ownership.nature: Securities held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power.

SEC source: 0001673232-26-000013 · primarydocument.xml · nonDerivative · entry 3

BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 25,915

F3 · shares: Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units.

F2 · ownership.nature: Securities held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power.

SEC source: 0001673232-26-000013 · primarydocument.xml · nonDerivative · entry 2

BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 33,752

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F2 · ownership.nature: Securities held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power.

SEC source: 0001673232-26-000013 · primarydocument.xml · nonDerivative · entry 1

BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 17,790

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F2 · ownership.nature: Securities held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power.

SEC source: 0001106578-26-000012 · primarydocument.xml · derivative · entry 11

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 37,080 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F7 · derivative.exercise_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2026.

F7 · derivative.expiration_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2026.

SEC source: 0001106578-26-000012 · primarydocument.xml · derivative · entry 10

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,499 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F7 · derivative.exercise_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2026.

F7 · derivative.expiration_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2026.

SEC source: 0001106578-26-000012 · primarydocument.xml · nonDerivative · entry 4

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,513

F2 · shares: Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units.

SEC source: 0001106578-26-000012 · primarydocument.xml · nonDerivative · entry 3

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,072

F2 · shares: Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units.

SEC source: 0001106578-26-000012 · primarydocument.xml · nonDerivative · entry 2

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,709

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.